AnalystBook Research · Company Intelligence

Amesite Inc.

AMSTNasdaq

Built from Amesite Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Amesite revenue fell 33.8% to $110.5K, the net loss narrowed to $3.6M, and free cash flow remained negative.

The read at a glance✓ Audited against SEC data
  • Business mix — AI healthcare workflow toolsNote
  • Revenue — Revenue fell 33.8% to $110.5KWatch
  • Profitability — Net loss narrowed 17.9%Note
  • Cash — Free cash flow was -$2.5MWatch
  • Balance sheet — Equity rose 8.9%OK
  • Insiders — 0 buys / 0 sellsNote
  • Accounting — Altman-Z distress; EQ greyWatch

Business

Amesite is a technology company building AI-powered healthcare workflow products under the NurseMagic brand, with both direct-to-practitioner and enterprise offerings.

Where the revenue comes from

Fiscal 2026, as Amesite Inc. reports it. History and quarterly detail are in the app.

  • Business (B2B)$298K
  • Individuals (B2C)$67K

Leadership changes

From Amesite Inc.'s own filings, the day they're filed.

  • Anthony Barkett · Directors · departureeff. 2024-12-23
  • Richard Ogawa · departureeff. 2024-12-23

Latest filings

  • 10-K · Annual report2026-09-23
  • 8-K · Company announcement2026-09-17
  • 8-K · Company announcement2026-09-11
  • 8-K · Company announcement2026-07-20
  • 8-K · Company announcement2026-07-13
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Amesite Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.